Last updated: 11/03/2018 16:01:45

Meta-analysis of efficacy of Topotecan

GSK study ID
114015
See study documents
Clinicaltrials.gov ID
NCT01160185
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Meta-analysis of efficacy of Topotecan and other treatments for recurrent carcinoma of the cervix
Trial description: This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Survival

Timeframe: 12 months

Secondary outcomes:
Not applicable
Interventions:
  • Drug: paclitaxel
  • Drug: cisplatin
  • Drug: topotecan
    • Enrollment:
    1
    Primary completion date:
    Not applicable
    Observational study model:
    Other
    Time perspective:
    Retrospective
    Clinical publications:
    Not applicable
    Medical condition
    Cervical Intraepithelial Neoplasia
    Product
    topotecan
    Collaborators
    Not applicable
    Study date(s)
    June 2009 to July 2009
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female
    Age
    21+ years
    Accepts healthy volunteers
    No
    • Randomised Clinical Trials or systematic reviews or meta-analyses
    • Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease
    • None
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Randomised Clinical Trials or systematic reviews or meta-analyses
    • Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease
    Exclusion criteria:
    • None

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2009-08-07

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website